ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2009
Recent advances in the management of mucormycosis: from bench to bedside.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
198 citing papers in PubMed, 2 syntheses or guidelines pooled it, 541 citations in OpenAlex.
- Use of isavuconazole in mucormycosis: a systematic review.BMC infectious diseases · 2025Pooled it
- Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Haematologica · 2013Guideline
- Risk factors for mortality in patients with mucormycosis.Medical mycology · 2012Trial
- The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.The Journal of antimicrobial chemotherapy · 2012Trial
- Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.Antimicrobial agents and chemotherapy · 2012Trial
- Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Antimicrobial agents and chemotherapy · 2010Trial
- Clinical and Economic Trade-Offs in Antifungal Therapy for Invasive Aspergillosis and Mucormycosis: A Markov Model-Based Analysis.Journal of fungi (Basel, Switzerland) · 2026Article
- All That Swells Is Not Allergy: Unmasking Rhino-Orbital-Cerebral Mucormycosis in Diabetic Ketoacidosis.Cureus · 2026Article
- Repurposing antiviral agents against mucormycosis.PloS one · 2026Article
- Frontal Sinus Endoscopy in Combined Approach Frontal Sinusotomy for Post-COVID-19 Mucormycosis.Cureus · 2025Article
- Diabetes Mellitus and Infectious Diseases: Current Evidence and Clinical Implications.Diabetes & metabolism journal · 2025Review
- Rare case of hard palate mucomycosis complicated by peri-orbital swelling: A diagnostic challenge.Radiology case reports · 2025Article
- Unmasking Histoplasmosis: A Diagnostic Challenge of Pediatric Febrile Neutropenia in an Immunocompromised Patient.Cureus · 2025Article
- Recent Trend of Surge in Pulmonary involvement in Sinonasal Mucormycosis: A Case Series: Pulmonary involvement in Sinonasal Mucormycosis.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Synthesis of Chitosan based nanoemulsions and their characterization and antifungal activity toward fungi causing mucormycosis.Scientific reports · 2025Article
- Development and evaluation of a Pan-Mucorales Real-time PCR and a multiplex Real-time PCR for detection and identification ofJournal of clinical microbiology · 2025Article
- Commemorating the Landmark Advances in Our Understanding of Mucormycosis by Dimitrios P. Kontoyiannis.Journal of fungi (Basel, Switzerland) · 2025Article
- Cutaneous mucormycosis: Unveiling rare manifestations.Journal of family medicine and primary care · 2025Article
- Preoperative Administration of Amphotericin B in Orbital Mucormycosis Management: A Case Report.Journal of neurological surgery reports · 2025Article
- Intra-abdominal Mucormycosis in an Immunocompetent Host: A Rare Presentation and Literature Review.Cureus · 2025Article
138 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Recent therapeutic advances have the potential to improve outcomes of mucormycosis. Lipid formulations of amphotericin B (LFAB) have evolved as the cornerstone of primary therapy for mucormycosis. Posaconazole may be useful as salvage therapy, but it cannot be recommended as primary therapy for mucormycosis on the basis of available data. Preclinical and limited retrospective clinical data suggest that combination LFAB-echinocandin therapy may improve survival during mucormycosis. A definitive trial is needed to confirm these results. Combination therapy with LFAB and the iron chelator, deferasirox, also improved outcomes in animal models of mucormycosis. In contrast, combination polyene-posaconazole therapy was of no benefit in preclinical studies. Adjunctive therapy with recombinant cytokines, hyperbaric oxygen, and/or granulocyte transfusions can be considered for selected patients. Early initiation of therapy is critical to maximizing outcomes; recent developments in polymerase chain reaction technology are advancing early diagnostic strategies. Prospective, randomized clinical trials are needed to define optimal management strategies for mucormycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.